Meds A-Z

Mometasone

Detailed information about Mometasone

Official label facts Owner quick guide first Marketing clearly labeled

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

For the treatment of otitis externa in dogs associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ).

What it does:

When it's needed:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For otic use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Call your vet sooner if you notice:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For otic use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Commonly reported reactions:

(1 reports)
(1 reports)
(1 reports)

What to ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Talk to a Vet / Find a Vet Near You

Image coming soon

Mometasone

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: MSK

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: MSK

Form: Liquid (Suspension), Otic Suspension, Solution, Suspension, Topical Suspension

Identifiers:

ANADA: 200536 ANADA: 200719 ANADA: 200829 NADA: 141177 NADA: 141266 NADA: 141440 NADA: 141600 NDC Package: 0061-0089-01 NDC Package: 0061-0089-02 NDC Package: 0061-0089-03 NDC Package: 0061-1246-01 NDC Package: 0061-1246-02 NDC Package: 0061-1246-04 NDC Package: 0061-1246-05 NDC Package: 0061-5432-01 NDC Package: 13985-701-07 NDC Package: 13985-701-15 NDC Package: 13985-701-21 NDC Package: 13985-701-30 NDC Package: 17030-001-10

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200829 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141177 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For otic use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For otic use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Most Reported Reactions

Cases	Species	Serious cases
1	Dog	1
1	Dog	1
1	Dog	1
1	Dog	1
1	Cat	0
1	Cat	0
1	Dog	0
1	Cat	0

Species coverage: Cat (17) Dog (15)

View detailed reaction table

Species	Seriousness	Frequency	Reports
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Non-serious	-	1
Dog	Serious	-	1
Cat	Non-serious	-	1
Dog	Serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Serious	-	1
Dog	Serious	-	1
Cat	Non-serious	-	1
Dog	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Unknown	-	-
Cat	Unknown	-	-
Dog	Unknown	-	-
Cat	Unknown	-	-
Cat	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Cat	Unknown	-	-
Cat	Unknown	-	-
Dog	Unknown	-	-
Dog	Unknown	-	-
Cat	Unknown	-	-
Dog	Unknown	-	-
Cat	Unknown	-	-
Cat	Unknown	-	-
Dog	Unknown	-	-

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2024-US-077320

Storage & Handling

No storage/handling guidance is linked yet.

Source metadata: No source yet.

Documents

Official label facts are separated from secondary summaries.

Official documents: 16 • Secondary summaries: 0

Official label facts

FOI Summary oA 200-829 Approved December 22, 2025.pdf · FOI
Klentz™ · SPL
ucm117269.pdf · FOI
ucm117268.pdf · FOI
ucm117265.pdf · FOI
Mometamax™ Otic Suspension · SPL
FOI Summary oN 141-600 Approved April 29 2025_ef.pdf · FOI
Mometamax Single™ · SPL
FOI Summary oA 200-719 Approved September 28, 2022.pdf · FOI
SIMPLERA™ · SPL
UCM465253.pdf · FOI
CLARO™ · SPL
UCM256757.pdf · FOI
Posatex® Otic Suspension · SPL
UCM504539.pdf · FOI
Mometavet® · SPL

Secondary summaries

No source yet.

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17828 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18162/Klentz%E2%84%A2 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/689 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/688 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/687 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/489/Mometamax%E2%84%A2%20Otic%20Suspension · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/16869 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17190/Mometamax%20Single%E2%84%A2 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/12934 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13011/SIMPLERA%E2%84%A2 · document · SPL

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.

Talk to a Vet / Find a Vet Near You

Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Feb 9, 2026, 3:15 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:22 AM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: CLARO™ Klentz™ Mometamax Single™ Mometamax™ Otic Suspension Mometavet® Posatex® Otic Suspension SIMPLERA™

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Dog

Rx/OTC: RX

Form/route: Liquid (Suspension), Otic Suspension, Solution, Suspension, Topical Suspension • Otic, Topical

Applications: ANADA 200-829 • NADA 141-177 • NADA 141-600 • ANADA 200-719 • NADA 141-440 • NADA 141-266 • ANADA 200-536

Documents: 9 (FOI: 9) • SPL: 7 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 8 • Cat 8 • View

Case summaries: 10 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Otitis Externa (Ear Infection)

Linked using: Fda_Label (0.95)

Diagnosis Codes

ICD10_CM: H60.90

Otitis externa, unspecified ear

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For otic use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)

Top reaction signals

Cough (1) Diarrhoea (1) Drug administration duration too long (1) Lack of efficacy - NOS (1) Loss of hearing (1) Medication error NOS (1) Nasal discharge (1) Neurological signs NOS (1) No sign (1) Product compounding error (1) Twitching (1) Tympanic rupture (1) Unclassifiable adverse event (1) Uncomfortable (1) Upper respiratory sounds (1) Vomiting (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
0061-0089-01	0061	-
0061-0089-02	0061	-
0061-0089-03	0061	-
0061-1246-01	0061	-
0061-1246-02	0061	-
0061-1246-04	0061	-
0061-1246-05	0061	-
0061-5432-01	0061	-
13985-701-07	13985	-
13985-701-15	13985	-
13985-701-21	13985	-
13985-701-30	13985	-
17030-001-10	17030	-
17033-273-15	17033	-
17033-273-21	17033	-
17033-273-30	17033	-
17033-273-75	17033	-
51072-122-00	51072	-
51072-122-01	51072	-
51072-122-02	51072	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

FOI Summary oA 200-829 Approved December 22, 2025.pdf • FOI summary • Official • Jan. 5, 2026
FDA FOI summary for application 200829
ucm117265.pdf • FOI summary • Official • Dec. 3, 2025
FDA FOI summary for application 141177
ucm117268.pdf • FOI summary • Official • Dec. 3, 2025
FDA FOI summary for application 141177
ucm117269.pdf • FOI summary • Official • Dec. 3, 2025
FDA FOI summary for application 141177
FOI Summary oN 141-600 Approved April 29 2025_ef.pdf • FOI summary • Official • June 3, 2025
FDA FOI summary for application 141600
FOI Summary oA 200-719 Approved September 28, 2022.pdf • FOI summary • Official • Oct. 3, 2022
FDA FOI summary for application 200719
UCM465253.pdf • FOI summary • Official • Aug. 3, 2021
FDA FOI summary for application 141440
UCM256757.pdf • FOI summary • Official • March 23, 2020
FDA FOI summary for application 141266
UCM504539.pdf • FOI summary • Official • Aug. 16, 2016
FDA FOI summary for application 200536

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 12 Clinical 0 Manufacturer 0 Marketing 0

Current Field Facts

contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For otic use in dogs only. Federal law restricts this drug to use by or o… (Official, 2026-02-12)
side_effects: Top reported reactions (openFDA): Temporary deafness, PR-EAR(S), LESION(S), Loss of hearing, Deafness, Lethargy (see also Central nervous system depression in … (Official, 2026-02-12)
usage: For the treatment of otitis externa caused by susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Pseudomonas species [including P. aerugi… (Official, 2026-02-12)

Recent Revisions

side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Klentz™ RX Florfenicol Mometasone furoate Terbinafine Solution • Otic Label highlights Official documents	Aurora Pharmaceutical, Inc.	ANADA 200-829	Approved	Jan 5, 2026
Mometamax™ Otic Suspension RX Clotrimazole Gentamicin Sulfate Mometasone Furoate Monohydrate Liquid (Suspension) • Topical Label highlights Official documents	Intervet, Inc.	NADA 141-177	Approved	Dec 3, 2025
Mometamax Single™ RX Gentamicin Mometasone furoate posaconazole Otic Suspension • Otic Label highlights Official documents	Intervet, Inc.	NADA 141-600	Approved	Jun 3, 2025
SIMPLERA™ RX Florfenicol Mometasone furoate Terbinafine Solution • Otic Label highlights Official documents	Vetoquinol USA, Inc.	ANADA 200-719	Approved	Oct 3, 2022
CLARO™ RX Florfenicol Mometasone furoate Terbinafine Solution • Otic Label highlights Official documents	Elanco US Inc.	NADA 141-440	Approved	Aug 3, 2021
Posatex® Otic Suspension RX Mometasone Furoate Monohydrate Orbifloxacin posaconazole Topical Suspension • Otic Label highlights Official documents	Intervet, Inc.	NADA 141-266	Approved	Mar 23, 2020
Mometavet® RX Clotrimazole Gentamicin Sulfate Mometasone furoate Suspension • Otic Label highlights Official documents	Med-Pharmex, Inc.	ANADA 200-536	Approved	Aug 16, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications

16.6 mg/mL florfenicol, 14.8 mg/mL terbinafine (equivalent to 16.6 mg/mL terbinafine hydrochloride) and 2.2 mg/mL mometasone furoate

Dogs

Indication

For the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

Dosage

Administer one dose (1 dropperette) per affected ear.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each gram contains 3 mg gentamicin base; mometasone furoate monohydrate equivalent to 1 mg mometasone furoate; and 10 mg clotrimazole, in a mineral oil-based system containing a plasticized hydrocarbon gel.

Dogs

Indication

For the treatment of otitis externa caused by susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Pseudomonas species [including P. aeruginosa], coagulase-positive staphylococci, Enterococcus faecalis, Proteus mirabilis, and beta-hemolytic streptococci).

Dosage

For dogs weighing less than 30 lbs, instill 4 drops from the 7.5g, 15g, or 30g bottle into the ear canal (2 drops from the 215g bottle) or, for dogs weighing 30 lbs or more, instill 8 drops from the 7.5g, 15g or 30g bottle into the ear canal (4 drops from the 215g bottle), once daily for 7 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

A 0.8 mL dose delivers 6.88 mg gentamicin, 2.08 mg posaconazole, and 1.68 mg mometasone furoate.

Dogs

Indication

For the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius and Pseudomonas aeruginosa) in dogs.

Dosage

Mometamax Single™ should be administered by veterinary personnel. The dose volume is 0.8 mL per affected ear. Verify the tympanic membrane is intact prior to administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

16.6 mg/mL florfenicol, 14.8 mg/mL terbinafine (equivalent to 16.6 mg/mL terbinafine hydrochloride) and 2.2 mg/mL mometasone furoate

Dogs

Indication

For the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

Dosage

Administer one dose (1 dropperette) per affected ear.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

16.6 mg/mL florfenicol, 14.8 mg/mL terbinafine (equivalent to 16.6 mg/mL terbinafine hydrochloride), 2.2 mg/mL mometasone furoate

Dogs

Indication

CLARO™ is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

Dosage

Administer one dose (1 dropperette) per affected ear. The duration of effect should last 30 days.

Limitations

For otic use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each gram of POSATEX Otic Suspension contains 10 mg orbifloxacin; mometasone furoate monohydrate equivalent to 1 mg mometasone furoate; and 1 mg posaconazole in a mineral oil based system containing a plasticized hydrocarbon gel.

Dogs

Indication

POSATEX Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis).

Dosage

For dogs weighing less than 30 lbs. instill 4 drops of POSATEX Otic Suspension once daily into the ear canal. For dogs weighing 30 lbs. or more, instill 8 drops once daily into the ear canal. Therapy should continue for 7 consecutive days. Four drops of POSATEX Otic Suspension delivers approximately 1.0 mg of orbifloxacin, 0.1 mg of mometasone furoate monohydrate, and 0.1 mg of posaconazole.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each gram contains gentamicin sulfate, USP equivalent to 3 mg gentamicin base; mometasone furoate anhydrous, USP equivalent to 1 mg mometasone; and 10 mg clotrimazole, USP.

Dogs

Indication

For the treatment of otitis externa in dogs caused by susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Pseudomonas spp. [including P. aeruginosa], coagulase- positive staphylococci, Enterococcus faecalis, Proteus mirabilis, and beta-hemolytic streptococci).

Dosage

For dogs weighing less than 30 lbs, instill 4 drops from the 7.5 g tubes and bottles, 15 g tubes and bottles, and 30 g bottles (2 drops from the 215 g bottle) once daily in the ear canal. For dogs weighing 30 lbs or more, instill 8 drops from the 7.5 g tubes and bottles, 15 g tubes and bottles, and 30 g bottles (4 drops from the 215 g bottle) once daily in the ear canal. Therapy should continue for 7 consecutive days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents

FOI FOI Summary oA 200-829 Approved December 22, 2025.pdf

Summary

For the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

SPL Packages

Klentz™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI ucm117269.pdf

Summary

New package size (7.5g bottle)
FOI ucm117268.pdf

Summary

For the treament of otitis externa caused by susceptible strains of yeast ( Malassezia pachydermatis) and certain bacteria ( Pseudomonas supp. including P. aeruginosa, coagulase positive staphylococci, Enterococcus faecalis, Proteus mirabilis and beta-hemolytic streptococci).
FOI ucm117265.pdf

Summary

Mometamax™ Otic Suspension is indicated for the treatment of otitis externa associated with yeast (Malassezia pachydermatis) and/or bacteria susceptible to gentamicin in dogs.

SPL Packages

Mometamax™ Otic Suspension (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oN 141-600 Approved April 29 2025_ef.pdf

Summary

For the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius and Pseudomonas aeruginosa) in dogs.

SPL Packages

Mometamax Single™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-719 Approved September 28, 2022.pdf

Summary

For the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

SPL Packages

SIMPLERA™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM465253.pdf

Summary

For the treatment of otitis externa in dogs associated with susceptible strains of yeast ( Malassezia pachydermatis) and bacteria ( Staphylococcus pseudintermedius).

SPL Packages

CLARO™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM256757.pdf

Summary

POSATEX Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis).

SPL Packages

Posatex® Otic Suspension (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM504539.pdf

Summary

For the treatment of otitis externa in dogs caused by susceptible strains of yeast ( Malassezia pachydermatis) and bacteria ( Pseudomonas spp. [including P. aeruginosa], coagulase- positive staphylococci, Enterococcus faecalis, Proteus mirabilis, and beta-hemolytic streptococci).

SPL Packages

Mometavet® (ZIP)

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of otitis externa caused by susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Pseudomonas species [including P. aeruginosa ], coagulase-positive staphylococci, Enterococcus faecalis , Proteus mirabilis , and beta-hemolytic streptococci). POSATEX Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa , and Enterococcus faecalis ). CLARO™ is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ).

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For otic use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

No approved side-effect narrative is linked yet.

openFDA reaction signals are available for Dog 8 and Cat 8 (view top reported reactions).

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog

Digestive

Vomiting (5)

Neurologic

Tiredness (lethargy) (5)

Other

Temporary deafness (460) PR-EAR(S), LESION (275) Loss of hearing (227) Deafness (67) Partial deafness (4) Allergic skin reaction (3)

Cat

Digestive

Diarrhea (1)

Effectiveness

Lack of efficacy - NOS (1)

Other

Unclassifiable adverse event (2) Cough (1) Nasal discharge (1) No sign (1) Product compounding error (1) Upper respiratory sounds (1)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Unknown • Drug: MSK, Suspension • Reactions: Twitching, Neurological signs NOS • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-046411
Serious AE: Yes
Treated For AE: No
Sex: Unknown

Case-reported brand: MSK
Case-reported manufacturer: MSK
Form: Suspension

Reactions Reported:

Twitching Neurological signs NOS

Outcomes: Outcome Unknown

Dog, Retriever - Labrador, Male, 14 year, 27.669 kilogram • Drug: MSK, Suspension, Auricular (Otic), Dose: 8 drops per animal, Frequency: 1 per day • Reactions: Loss of hearing, Drug administration duration too long • Outcome: Recovered with Sequela

Report ID: USA-USFDACVM-2025-US-046917
Serious AE: No
Treated For AE: No
Sex: Male
Age: 14.00 Year
Weight: 27.669 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Auricular (Otic)
Form: Suspension
Dose: 8 drops per animal
Frequency: 1 per day

Reactions Reported:

Loss of hearing Drug administration duration too long

Outcomes: Recovered with Sequela

Cat, Norwegian Forest, Male, 10 month, 5 kilogram • Drug: MSK, Unknown • Reactions: No sign, Product compounding error

Report ID: USA-USFDACVM-2025-US-025803
Serious AE: No
Treated For AE: No
Sex: Male
Age: 10.00 Month
Weight: 5.000 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

No sign Product compounding error

Dog, Terrier - Yorkshire, Female, 14 year • Drug: MSK, Suspension • Reactions: Loss of hearing, Medication error NOS, Tympanic rupture • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-017514
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 14.00 Year

Case-reported brand: MSK
Case-reported manufacturer: MSK
Form: Suspension

Reactions Reported:

Loss of hearing Medication error NOS Tympanic rupture

Outcomes: Outcome Unknown

Dog, Male, 12 year, 10.9 kilogram • Drug: MSK, Suspension • Reactions: Loss of hearing • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-010498
Serious AE: No
Treated For AE: No
Sex: Male
Age: 12.00 Year
Weight: 10.900 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Form: Suspension

Reactions Reported:

Loss of hearing

Outcomes: Ongoing

Dog, Shepherd Dog - Australian, Male, 11 year, 24.9 kilogram • Drug: MSK, Suspension • Reactions: Loss of hearing, Uncomfortable • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-014406
Serious AE: No
Treated For AE: Yes
Sex: Male
Age: 11.00 Year
Weight: 24.900 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Form: Suspension

Reactions Reported:

Loss of hearing Uncomfortable

Outcomes: Ongoing

Cat, British cat, Female, 3 month, 1.5 kilogram • Drug: MSK, Suspension • Reactions: Cough, Nasal discharge, Upper respiratory sounds • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2024-US-077320
Serious AE: No
Treated For AE: No
Sex: Female
Age: 3.00 Month
Weight: 1.500 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Form: Suspension

Reactions Reported:

Cough Nasal discharge Upper respiratory sounds

Outcomes: Outcome Unknown

Cat, Female, 7 month, 2.84 kilogram • Drug: MSK, Suspension • Reactions: Lack of efficacy - NOS, Diarrhea • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2024-US-069150
Serious AE: No
Treated For AE: No
Sex: Female
Age: 7.00 Month
Weight: 2.840 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Form: Suspension

Reactions Reported:

Lack of efficacy - NOS Diarrhea

Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on PetWisePlus are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Mometasone

Pet Owner Quick Guide

Mometasone

Quick Facts

Warnings / Contraindications

Adverse Reactions

Most Reported Reactions

Storage & Handling

Documents

Promotional Materials (Marketing)

At a Glance

Counseling and Monitoring Highlights

Identifiers & Packages

Enriched Documents

Data Sources & Revision History

FDA Products & Applications (Animal Drugs @ FDA)

What It's For (FDA Label Highlights)

Klentz™ • Solution • Otic

Mometamax™ Otic Suspension • Liquid (Suspension) • Topical

Mometamax Single™ • Otic Suspension • Otic

SIMPLERA™ • Solution • Otic

CLARO™ • Solution • Otic

Posatex® Otic Suspension • Topical Suspension • Otic

Mometavet® • Suspension • Otic

Official Documents (FDA)

Klentz™ • 200829

Mometamax™ Otic Suspension • 141177

Mometamax Single™ • 141600

SIMPLERA™ • 200719

CLARO™ • 141440

Posatex® Otic Suspension • 141266

Mometavet® • 200536

Usage

Contraindications

Side Effects

Top Reported Reactions (openFDA)

Adverse Event Case Summaries (openFDA)

Aug 14, 2025 • Dog • Twitching, Neurological signs NOS • Outcome Unknown

Jul 14, 2025 • Dog • Retriever - Labrador • Loss of hearing, Drug administration duration too long • Recovered with Sequela

Apr 22, 2025 • Cat • Norwegian Forest • No sign, Product compounding error

Mar 26, 2025 • Dog • Terrier - Yorkshire • Loss of hearing, Medication error NOS • Outcome Unknown

Mar 4, 2025 • Dog • Loss of hearing • Ongoing

Feb 25, 2025 • Dog • Shepherd Dog - Australian • Loss of hearing, Uncomfortable • Ongoing

Dec 9, 2024 • Cat • British cat • Cough, Nasal discharge • Outcome Unknown

Nov 6, 2024 • Cat • Lack of efficacy - NOS, Diarrhea • Outcome Unknown

Overdose Information

Storage & Handling

Share Your Thoughts